Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer ’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference

TOKYO and CAMBRIDGE, November 29, 2022 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, " Eisai " ) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, " Biogen " ) announced today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials